Sunzen Group Berhad (“Sunzen” or “the Group”), an established player in Malaysia’s health products, medical devices and services, and loan financing with a diversified portfolio, today announced its unaudited financial results for the fourth quarter ended 30 June 2026 (“Q4 FY2026”), recording revenue of RM19.62 million and profit before tax (“PBT”) of RM2.40 million.
For the financial year ended 30 June 2026 (“FYE2026”), the Group recorded revenue of RM93.51 million, representing an increase of 16.1% from RM80.58 million in the previous financial year. PBT increased significantly to RM15.89 million from RM3.31 million previously, mainly underpinned by higher profit contribution in line with increased revenue, successful recovery of bad debts, as well as lower overall operating expenses incurred during the year.
For Q4 FY2026, the Group’s revenue increased 31.0% year-on-year to RM19.62 million from RM14.98 million in the corresponding quarter last year, driven by growth across all business segments. The Group also returned to profitability with PBT of RM2.40 million, compared to a loss before tax (“LBT”) of RM0.53 million previously.
Quarter-on-quarter (“QoQ”), revenue declined 18.2% from RM23.97 million in Q3 FY2026, while PBT decreased 23.6% from RM3.15 million. The sequential moderation was mainly attributable to lower revenue contribution from the Human Health segment, particularly lower export revenue of edible bird’s nest to the China market. Earnings were also impacted by higher operating expenses, specifically a RM0.84 million bad debt write-off and RM0.69 million inventory write-down during the quarter.
The Human Health segment recorded revenue of RM10.77 million in Q4 FY2026, representing an increase of 22.5% from RM8.79 million in the corresponding quarter last year. Despite the higher revenue, the segment recorded LBT of RM2.78 million, compared to LBT of RM0.87 million previously, mainly due to higher operating expenses, specifically bad debt write-off and inventory write-down. For FYE2026, the segment’s revenue increased 11.9% to RM63.86 million from RM57.07 million, while LBT stood at RM2.33 million compared to RM1.77 million previously.
The Medical Devices and Services segment continued its positive growth momentum, with quarterly revenue increasing 62.3% year-on-year to RM3.32 million from RM2.05 million, while PBT increased 66.7% to RM0.71 million from RM0.43 million, supported by stronger revenue generated during the quarter. For FYE2026, the segment recorded revenue of RM9.83 million and PBT of RM1.67 million, compared to RM6.96 million and RM1.15 million respectively in the corresponding nine-month period following the acquisition of the business in October 2024.
The Loan Financing segment remained the Group’s key earnings anchor, with quarterly revenue increasing 33.5% year-on-year to RM5.54 million from RM4.15 million, driven by higher financing volume. PBT surged to RM4.70 million from RM0.82 million in the corresponding quarter, supported by higher revenue contribution and successful recovery of bad debts, while the comparative quarter was affected by a RM2.97 million bad debts write-off. For FYE2026, revenue increased 44.3% to RM19.83 million from RM13.74 million, while PBT more than doubled to RM15.50 million from RM7.26 million.
Group Managing Director of Sunzen Group Berhad, Mr. Teo Yek Ming said,
“FYE2026 marked a significant improvement in the Group’s overall profitability, with PBT increasing substantially to RM15.89 million. The performance reflects the strength of our diversified business portfolio, particularly the continued growth of our Loan Financing and Medical Devices and Services segments.
While our Human Health segment continued to face near-term cost pressures, we are encouraged by the growth in revenue and are taking steps to strengthen its distribution reach and operational efficiency. Moving forward, we will remain focused on building sustainable earnings across our core businesses while maintaining prudent cost and risk management.”
Looking ahead, Sunzen remains cautiously optimistic on its prospects. The Human Health segment is expected to improve, supported by a ramp-up in customer sales orders. To broaden its regional presence, Ecolite has appointed a local distributor in Indonesia and commenced applications for the relevant product registrations and Halal certification, while also exploring suitable distribution opportunities in Singapore and East Malaysia.
The segment also plans to introduce a subscription model for selected products to diversify its sales channels and strengthen recurring customer engagement. In view of rising utility and overhead costs, the Group will continue to manage its pricing and costs accordingly, while demand from the China market is expected to remain stable and comparable to the corresponding period last year.
The Medical Devices and Services segment is expected to maintain positive operational momentum, supported by deeper hospital penetration, an expanded ophthalmic device portfolio and strengthened relationships with key ophthalmologists and healthcare groups. Rising demand for diagnostic and surgical technologies is expected to provide further growth opportunities, while Eye Nation Medical will continue to focus on expanding its market share, improving margin and operational efficiency, and introducing new product verticals to support sustainable long-term growth.
Meanwhile, demand for alternative financing solutions remains resilient, particularly among small and medium-sized enterprises (“SMEs”). While overall loan growth is expected to moderate, the Loan Financing segment will continue to adopt a prudent and selective lending approach, focusing on secured lending, stringent credit assessments and higher-quality borrowers with stronger repayment profiles to support the quality and sustainability of its financing portfolio.
For more information, visit www.sunzengroup.com
